NIH sponsored a meeting of medical and veterinary pathologists with mammary gland expertise in Annapolis in March 1999. Rapid development of mouse mammary models has accentuated the need for de®nitions of the mammary lesions in genetically engineered mice (GEM) and to assess their usefulness as models of human breast disease. The panel of nine pathologists independently reviewed material representing over 90% of the published systems. The GEM tumors were found to have: (1) phenotypes similar to those of non-GEM; (2) signature phenotypes speci®c to the transgene; and (3) some morphological similarities to the human disease. The current mouse mammary and human breast tumor classi®cations describe the majority of GEM lesions but unique morphologic lesions are found in many GEM. Since little information is available on the natural history of GEM lesions, a simple morphologic nomenclature is proposed that allows direct comparisons between models. Future progress requires rigorous application of guidelines covering pathologic examination of the mammary gland and the whole animal. Since the phenotype of the lesions is an essential component of their molecular pathology, funding agencies should adopt policies ensuring careful morphological evaluation of any funded research involving animal models. A pathologist should be part of each research team. Oncogene (2000) 19, 968 ± 988.
Introduction
Genetic engineering of mice for mammary biology is now in its second decade. Almost 100 transgenes, targeted mutations (site-directed mutations, knock outs and knock ins), combinations of transgenes and combinations of transgenes and targeted mutations have been used to study mammary cancer in mice. These mice will be referred to here under the collective term of Genetically Engineered Mice (GEM). Surprisingly few reports provide detailed analysis of the tumor pathology or the natural history and evolution of neoplastic progression. Although many investigators have claimed that their animals are models for human breast cancer, few have actually validated their models and provided direct comparisons with human tissues.
The National Institutes of Health (NIH) Breast Cancer Think Tank (BCTT), an internal organization responsible for determining key issues in breast cancer, identi®ed that the accurate pathologic analysis of lesions in genetically engineered mice is a key to progress in understanding these models. On March 3 ± 5, 1999 , a panel of nine surgical, veterinary and experimental pathologists was convened in Annapolis Maryland, sponsored by the NIH, BCTT and the NCI Cancer Genome Anatomy Project (CGAP). The Panel was asked to compare the pathology and classi®cation of mouse and human breast cancers. The following report includes the considerations and recommendations of the Annapolis Pathology Panel and its organizers.
Materials and methods
A set of 175 slides representing 39 models of genetically engineered mice was developed through the generous donation of blocks and slides by investigators from around the world (summarized in Table 1 ). In addition, two models of transgenesis in rats, three transplant models, two models of chemical carcinogenesis and three examples of Mouse Mammary Tumor Virus (MMTV)-induced tumors were available for comparison. The slide set was developed, distributed and studied in advance of the meeting in Annapolis. The available experimental and demographic data was also provided for each model. In addition, the members of the Panel shared published and unpublished cases from their own archives that included their experience with over 50 additional model systems. The slide set was a unique opportunity to compare the histopathology of the majority of existing models.
Many of the biologists who created the GEM models attended the Annapolis meeting to present and discuss the biology of the individual models. The key publications were listed and available for the Panel. Special stains of selected cases were performed and available to the Panel for additional study.
Following the Annapolis meeting, the Pathology Panel continued their studies and deliberations, meeting for a ®nal review on July 26 and 27, 1999 at NIH, Bethesda, MD. The ®nal draft of this report was subsequently developed. This paper represents the collective views of the Panel.
Nomenclature

Historical background
A number of classi®cation schemes for both human and mouse mammary cancer were reviewed. Existing classi®cation schemes for mouse mammary tumors were developed to describe tumors that arose`spontaneously' (usually induced by mouse mammary tumor virus (MMTV)), or were induced by chemical carcinogens. The mouse mammary tumor classi®cation scheme developed by Dr Thelma Dunn and her colleagues has been widely used by veterinary pathologists and mammary biologists since its introduction in 1958 (Dunn, 1959; Sass and Dunn, 1979) . It has the charm of regarding the mammary masses found in mice as tumors' without necessarily designating them as benign or malignant. The tumors were given a letter designation that was initially based on frequency of occurrence: Type A, Type B and Type C. Later, additional letters were added to signify new or additional morphologically distinct tumor types. For example, the pregnancy dependent`tumor', also known as,`plaque', became Type P (Dunn, 1959; Sass and Dunn, 1979) . (Coey et al., 1994; Jhappan et al., 1990; Matsui et al., 1990; Sandgren et al., 1990 Sandgren et al., , 1995 ) TGF-b MMTV-infected Mouse WAP (Korden et al., 1995) Receptors TGFb DNIIR Mouse MMTV-LTR (Joseph et al., 1999) ERB-B2 (neu) p53-172H Mouse MMTV-LTR (Guy et al., 1992b; Li et al., 1997 , Muller et al., 1988 ) RET-1 Mouse MMTV-LTR (Iwamoto et al., 1990 ) Tpr-MET Mouse MMTV-LTR (Liang et al., 1996) Signal pathways PyV-mT Mouse MMTV-LTR (Guy et al., 1992a ) RAS Mouse MMTV-LTR (Sinn et al., 1987) Cell cycle CYCLIN D1 Mouse MMTV-LTR (Wang et al., 1984 ) MYC BCL-2 Mouse MMTV-LTR, WAP (Jager et al., 1997 , Stewart et al., 1984 Mouse WAP, Null (Donehower et al., 1992; Li et al., 1997) SV40TAg BCL-2 Mouse WAP, C(3)1 (Furth et al., 1999; Husler et al., 1998; Maroulakou et al., 1994; Tzeng et al., 1993) Dierentiation NOTCH4(INT3) TGFb Mouse MMTV-LTR, WAP (Gallahan et al., 1996; Smith et al., 1995 (Rehm and Liebelt, 1996) (Jerry et al., 1999) Subsequently, Rehm and Liebelt proposed a tissuebased classi®cation of the murine mammary lesions with a primary subdivision into alveolar, ductal and myoepithelial origin (Rehm and Liebelt, 1996) . While this biologically based classi®cation was a considerable improvement, neither the Dunn nor the tissue origin classi®cation describe the greater variety of mammary tumors that are seen in GEM models. The recognition of novel tumor types emerging in GEMS has necessitated the development of a new classi®cation scheme that would encompass these tumors.
The classi®cation of human breast cancer has a timehonored, clinically validated tradition that is widely accepted and applied around the world (Jensen et al., 1993; Page et al., 1998) . Descriptive terms such as medullary, cribriform, and others are understood and universally accepted. Unfortunately, the classi®cation always distinguished between`ductal' and`lobular'. This terminology is maintained, however, because of long-standing use and the knowledge that`lobular' carcinoma and`lobular' carcinoma in situ have morphologic patterns and clinical outcomes that are distinct from their`ductal' counterparts. Most authorities now agree that both types of tumors arise in the Terminal Ductal Lobular Unit (TDLU) (Cardi, 1998; Cardi and Munn, 1998; Cardi and Wellings, 1999; Russo et al., 1990; Wellings et al., 1976) . That is, they arise in the terminal ductules or alveoli, rather than in the collecting ducts as implied by the term`ductal'. So while the designations are useful, they give a misleading impression about the cellular origin of the tumor. This resolution of the controversy around ductal and lobular does not exclude the possibility that other human and murine tumors actually arise in the major ducts.
The mammary gland is anatomically divided into collecting ducts and the TDLU. The TDLU terminate in alveolar buds that share a common terminal ductule (see drawings in Figure 1 ) (Russo et al., 1990) . As will become apparent, the development of an anatomically correct classi®cation requires knowledge of the anatomy of the mouse mammary gland.
At birth the female mouse mammary gland parenchyma consists of a single primary main lactiferous duct that branches into three to ®ve secondary ducts. From the second to the ®fth weeks of life, continuous branching and sprouting leads to new ducts that vary in width and length. Some of the ducts are narrow and straight, ending in club shaped terminal end buds (TEBs) (Figure 1a ). This period of mammary gland development is identi®ed as the`ductal stage'. At the beginning of ovarian function and during sexual maturity, branching continues by budding of`lateral buds' that end in terminal ducts (TDs), or cleavage of Figure 1 From the second to the ®fth weeks of life, during the`ductal stage', the mammary tree grows by continuous branching and sprouting of new, ending in club shaped terminal end buds (TEBs) (a). The`alveolar bud stage' is characterized by budding of lateral buds' that end in terminal ducts (TDs), or cleavage of TEBs into two smaller buds, the`alveolar buds (ABs)'. (a,c). The ABs sprout new buds, referred to as`ductules' that cluster around the duct, forming a primitive lobule type 1 (Lob 1) signaling the beginning of the`lobular stage'. The primitive Lob 1 is composed of 6.26+4.10 ductules per cross section (a,d) and with increasing stimuli form more complex lobular structures such as the lobules type 2 (Lob 2) and type 3 (Lob 3). Lob 2 contain 22 ± 32 ductules per cross section (mean 26.64+5.22) (a,e). Lob 3 contain 53 ± 90 ductules per cross section (mean 69.50+13.59) (f). All the lobular ductules are associated with a duct, the intralobular terminal duct. As the ductules present in Lob 2 and Lob 3 start accumulating secretory material within the lumen they are called acini or alveoli. The mouse mammary lobular structures are surrounded mainly by fat and very small amounts of connective tissue (b ± f) (drawings and images provided by Dr Jose Russo) TEBs into two smaller buds, the`alveolar buds' (ABs). This stage is called the`alveolar bud stage' (Figure  1a ,c). The ABs, in turn, sprout new buds that are called ductules' at this stage. They cluster around the duct, forming a primitive lobular structure or lobule type 1 (Lob 1). The formation of Lob 1 signals the beginning of the`lobular stage' that progresses from the more primitive Lob 1, composed of 6.26+4.10 ductules per cross section (Figure 1a,d) , to more complex lobular structures such as the lobules type 2 (Lob 2) and type 3 (Lob 3). This development takes place during pregnancy or under hormonal stimulation. Lob 2 contain 22 ± 32 ductules per cross section (mean 26.64+5.22) ( Figure  1a ,e). Individual ductules are small, lined by a layer of cuboidal epithelium surrounded by myoepithelial cells. The centrally located lumen is small and devoid of secretion. Lob 3 contain 53 ± 90 ductules per cross section (mean 69.50+13.59) (Figure 1f ). All the ductules of the lobular structures drain into a common duct, called intralobular terminal duct. Ductules present in Lob 2 and Lob 3 accumulating secretory material within the lumen are called acini. The epithelial cells lining the lumen of the acini have vacuolated cytoplasm due to their content of lipids. During lactation, the acini become distended with milk. The distended acini become tightly packed and the boundaries between dierent lobules disappear. The individual lobules become very dicult to identify. At this point in the lactating gland, the term Lob 3 is no longer applicable.
The mammary lobules of mice dier from the lobules found in the human. The lobule in humans is embedded in a relatively loose connective tissue stroma that is surrounded by a denser connective tissue (Russo et al., 1990) . A clear demarcation between the intra-and interlobular spaces exists. In contrast, the lobular structures of the mouse mammary gland are surrounded mainly by fat and very small amount of connective tissue (Figure 1b ± f) (Cardi and Wellings, 1999; Russo et al., 1990) . Further, type 2 and type 3 lobules are found in the resting breasts of non-lactating, non-pregnant adult human females while the quiescent mammary gland of the mouse rarely has the more developed type 1 and type 2 lobules (Russo et al., 1990) .
Classi®cation of genetically engineered mouse (GEM) mammary lesions
For many of the GEM models examined, the only pathological material that was available for examination was the tumor itself. In the absence of adjacent mammary tissue, tissue from other mammary glands and mammary tissue at earlier stages of tumorigenesis, the Panel was generally unable to assess the natural history of the disease. Furthermore, the existing literature on these models frequently failed to adequately describe neoplastic progression in the system. Faced with these problems of incomplete clinical descriptions of the disease, the Panel found it dicult, and perhaps even misleading, to provide a diagnostic classi®cation that had biological signi®cance. As a result, the Pathology Panel highly recommends the use of a descriptive classi®cation of mammary lesions. The intent here is to correct the inadequacies of previous classi®cations and hold the classi®cation open for modi®cation as more detailed biological studies become available that clearly document the natural history of the disease in each model system.
The available evidence and our experience suggest that tumors arising in many GEM have morphological patterns that have seldom been observed in non-GEM virus-induced or carcinogen-induced mouse mammary tumors (Table 2) (Figures 2 and 3) . From this perspective, the histopathology of GEM mammary tumors is unique. GEM tumors have three notable phenotypes: (1) some transgenes produce tumors closely resembling non-GEM tumors ( Figure 2 ); (2) many transgenes produce tumors that have unique, transgene-speci®c phenotypes (signature tumors) ( Figure 4) ; and (3) some GEM produce tumors that mimic human breast cancer (Cardi and Wellings, 1999) . The new nomenclature is designed to accommodate all these tumor types.
Recommendations
Descriptors A series of morphological descriptors should be applied to the GEM neoplasms (Table 3) . Table 2 Comparison of classi®cation of mammary gland proliferative lesions
Annapolis nomenclature
Nomenclature used in this literature* (Dunn 1959; Rehm and Liebelt, 1996; Sass and Dunn, 1979) Cellular origin/dierentiation (Rehm and Liebelt, 1996) Table 3 include most of the patterns observed by the Panel in mouse mammary tumors (Figure 3 ). The descriptors can be expanded as new morphological patterns are observed in GEM mammary lesions. However, new descriptors should avoid adaptation of terms from human surgical pathology that have clinically or biologically proven outcomes unless the investigators have shown that the biology of the lesion is also similar to the corresponding human lesion. This will avoid the continued use of conceptually inaccurate terms and misnomers.
The scienti®c community should avoid many of the terms traditionally used in veterinary and medical surgical pathology of the mammary gland that have little or no biological signi®cance. For example, in surgical pathology, the words ductal and lobular in relationship to pre-malignant and malignant lesions are a now widely recognized misnomer since both neoplasms primarily originate from the terminal duct lobular unit (TDLU) (Cardi and Wellings, 1999; Russo et al., 1990; Wellings et al., 1976) . Only when the origin of a GEM tumor is actually documented should the terms ductal, ductular and alveolar be applied.
Modi®ers The descriptors may be modi®ed by a number of terms that provide additional conceptual information about the descriptors. The ®rst set of modi®ers includes terms that imply knowledge of the biological behavior of the lesion. The Panel recommends that the use of rigorous criteria be applied to each level of biological potential. Tables 2 and 3 to characterize the patterns observed in GEM. (a) is glandular with glands dilated by secretions. This image is from a WAP/TGFa tumor; (b) is acinar with small glandular structure with small lumens and minimal secretions. The image is from a MMTV-LTR/wnt10b tumor; (c) is cribriform with back-toback glands. The image is from a MMTV-LTR/myc tumor; (d) is papillary well dierentiated with ®nger-like projects of ®brovascular stroma covered with neoplastic epithelium. This image is from a MTV-LTR/TGFa mouse; (e) is solid with sheets of tumor cells with little or no intervening stroma. This image is from a MMTV/DNIIR tumor; (f) is sclerotic with a dense connective tissue stroma separating strands of invasive tumor cells. This image is from a MMTV-LTR/int-3 tumor; (g) shows invasion between muscle ®bers in a bigenic WAP/TGFa6WAP/myc tumor; (h) shows an expansile non-invasive pattern at the edge of an adenoma and lactating mammary gland in a bigenic WAP/p53 ± 1726WAP/TGFa mouse; (i) has necrosis at the center of a dilated glandular structure. This image is from a BLG/igf-2 tumor; (j) is a carcinosarcoma tumor with sarcomatous and carcinomatous components from a WAP/stromelysin-1 mouse; (k) is a mammary tumor with cartilaginous and osseous metaplasia from a WAP/stromelysin-1 mouse; (l) is an adenocarcinoma from a MMTV/heregulin mouse. The scale bar indicates 100 microns (a) Biological potential Hyperplastic mammary lesions (or physiologic hyperplastic lesions) Like all epithelial tissues, the mammary gland can react to damage by an insult or to physiological stimuli. In the case of the mammary gland, physiologically mediated hyperplasia by pregnancy or lactation is diuse. Chronic exposure to endogenous or exogenous prolactin often leads to a diuse reactive hyperplasia (Huseby et al., 1985) . A hyperplastic repair process can occur in response to epithelial damage. This hyperplasia can be due to in¯ammatory conditions that may be immune-mediated, infectious or traumatic and lead to The ras-type tumors have small, uniform nuclei without signi®cant pleomorphism with relatively abundant cytoplasm. The ras-type tumors tend to organize around blood vessels to form papillary type growth patterns. This tumor would be classi®ed as a papillary carcinoma, low grade. The ret-1-type tumor forms distinctive glands that are lined by large cells with very pleomorphic nuclei and relatively little cytoplasm and would be classi®ed as a glandular adenocarcinoma, high grade. The scale bar indicates 100 microns (a) multifocal or focal hyperplasia characterized by an orderly increase in the numbers of regenerative epithelial cells within the gland. In the mouse mammary gland, these repair processes are often accompanied by squamous metaplasia of the epithelium. The in¯ammatory or squamous nodules frequently found in the involuted glands of multiparous females are examples. The basement membrane of the secretory unit or duct is intact but the alveolar development is persistent with additional cell layers and lymphoid in®ltrates or ®brosis of the stroma. It is worth noting that many GEM models require hormonal stimulation (e.g. through continuous breeding or the application of pituitary isografts) in order to get high level of transgene expression. Thus, a physiological hyperplasia may be expected in many of these models systems, and information about hormonal manipulation of the system should be made available to the pathologist.
Precancerous mammary lesions (atypical hyperplasia, mammary intraepithelial neoplasia and carcinoma in situ) All cancers in humans and animals probably arise from single cells (Cardi, 1984; Morris and Cardi, 1987) . In speci®c tissues, however, the origin of cancer can be multicentric. A sequence of molecular events leads to a sequence of histological and histogenetic changes that produces an invasive carcinoma (Cardi, 1984) . The earliest visible histological changes in the both human and murine mammary glands are focal or multifocal hyperplasias primarily within the terminal ductule or alveolar bud or both (Cardi and Wellings, 1999) . While some growths may extend into the major ducts, few lesions appear to originate in the collecting ducts as is implied by the word`duct' or`ductal' ( Figure 5 ).
Preneoplasia in non-GEM mice Two types of precancerous lesions occur in MMTV-infected mice, the hyperplastic alveolar nodules (HAN) and the plaque (Cardi, 1984; Morris et al., 1990) . The HAN is a focal alveolar hyperplasia that stands out from the background of the non-lactating mammary gland as¯at, 1 ± 2 mm nodules. The HAN histologically resemble normal prelactating mammary gland but are clonal lesions with an experimentally proven, highly malignant potential. They are typically cytologic low-grade lesions with relatively normal nuclei but with increased DNA synthesis and mitotic rate. The plaques are virally induced lesions and start as circumscribed ductal proliferations that are pregnancy dependent and regress on parturition. The plaque appears during pregnancy as a¯at but palpable lesion with radiating ducts and a delicate connective tissue stroma. Following multiple pregnancies some of these lesions will continue to grow after the pregnancy has ended to form invasive carcinomas that dier in morphology from the hyperplastic lesions. Both lesions have interchangeably been referred to as plaque or type P tumor and this confuses the issue. Like the HAN, plaques are clonal proliferations that can progress to malignancy with hormone independence and invasion (Morris et al., 1990) . They also have relatively low-grade cytology.
MIN in GEM The spectrum of lesions analogous to hyperplasias with or without atypia and in situ carcinomas in humans, has rarely been observed within collecting ducts, terminal ducts or alveoli of mice until the advent of GEM ( Figure 5 ). Because the lesions described below appear to represent precursors to invasive carcinoma in the mammary gland and, in at least some models, have been shown to possess at least some of the molecular changes seen in invasive carcinomas (Shibata et al., 1996) , the term`mammary intraepithelial neoplasia' (MIN) is to be used for these lesions (Tavassoli, 1998) .
The reader should note that the de®nition of MIN recommended for the mouse mammary gland diers from that provided by Tavassoli for the human breast (Tavassoli, 1998) . The de®nition of MIN in the human breast, according to Tavassoli, includes hyperplasias without atypia (Tavassoli, 1998) . The MIN without atypia is, in part, an interpretation based on molecular evidence. However, similar evidence from GEM mammary hyperplasias is not available. Therefore, the consensus of the Annapolis Pathology Panel is that the use of MIN in mice should be limited to strict morphological criteria including atypical nuclear cytology. As the transplant and molecular biology of the focal hyperplasias with or without atypia is documented, the de®nitions can be altered.
MMTV-LTR/Int2(FGF3) and MMTV-LTR/ KGF(FGF8) models were particularly instructive in that they produced signature lesions that resembled the pattern seen in hormone dependent lesions (plaques or Type P tumors) of GR3/A mice. These lesions form circumscribed complex radiating ducts in dense connective tissue and are associated with insertional activation of FGF3 by MMTV (Morris et al., 1990) (Figure 2d) . Therefore, over-expression of the oncogene resulted in the same morphological lesion whether induced by the virus or inserted as a transgene. Of particular note is the production of these proliferative ductal lesions in GEM models has allowed the study of their evolution. When induced by a transgene, the lesions are irreversible, multifocal and benign. The invasive neoplasms that emerge from these focal lesions have a phenotype distinctly dierent from the precursor lesion and metastasize. Thus, these ductal hyperplasias are MIN and cannot be considered malignancies.
The majority of the MIN lesions observed to this point clearly originate in the TDLU. However, this could be related to the promotor used to generate the mice. The majority of current model systems use the MMTV long terminal repeat promotor/enhancer (MMTV-LTR) or the whey acidic protein promoter (WAP) that appear to produce alveolar lesions. However, in some models, such as C(3)1-promoted SV40 Tag (Figure 5b) , the earliest lesions appear to originate in the both the collecting ducts and the terminal ductules. In at least several other GEM, for example in MMTV/ or WAP/notch4 and MMTV-LTR/DIINR, the collecting ducts may have primary involvement, but further study of natural history in these models will be required to determine their origin. At this point in time, more thorough study of the earliest lesions using a combination of transplantation of the speci®c lesion and whole mounts and histology of the whole mammary gland are required to de®ne the origin of these lesions. Until these studies are completed and the biology understood, the Panel recommends a simpli®ed classification for MIN. In this simpli®ed classi®cation, the MIN lesions are to be classi®ed as low or high grade ( Figure 5 ). The low grade lesions are characterized by the presence of hyperchromatic duct, luminal and/or myoepithelial cells with little cytoplasm, more than one layer of atypical cells, intact basement membrane and an increased mitotic rate (Figure 5a,c) . High-grade lesions show more layers of epithelium, pleomorphism of nuclei and/or epithelial cells and/or an increase in mitotic ®gures (Figure 5b,d) . Filling of the lumen by these proliferative cells can occur but the basement membrane remains intact.
If the hyperplasia produces a palpable nodule with no histological evidence of a breach in the basement membrane, a diagnosis of adenoma is appropriate. If disruption of the basement membrane is seen with malignant appearing cells traversing the area of the former basement membrane, invasive carcinoma is diagnosed. In some cases, special stains such as PAS or anti-collagen IV might be required to demonstrate the loss of basement membrane.
The term MIN infers that such lesions are not tumors, neither adenomas nor carcinomas, but rather morphological intermediates between normal and cancer. They are putative preinvasive lesions with characteristics of both benign and malignant cells. While they are probably immortalized and probably not reversible, little research has been done to support this concept. They are thought to be essentially biologically identical to similar lesions seen in other conventional mouse mammary pre-cancers such as the HAN. The MIN in GEM frequently resembles many lesions in human epithelial tissues prior to or accompanying invasive carcinoma. MIN should, therefore, be considered neither as benign nor malignant lesions but rather a preneoplastic, protoneoplastic or premalignant state.
Adenomas dier from either MIN or carcinoma in that they are well-dierentiated local tumors that do not progress to malignancy. They have no malignant potential. When transplanted, they have limited local growth potential. In contrast, MIN lesions have cytological and histological atypical morphology and are thought to have malignant potential. Although the malignant potential has been amply demonstrated in non-GEM precancers, similar studies have not been systematically carried out in GEM-related MIN.
The terms dysplasia, atypia or atypical hyperplasia have also been used for lesions described above. We discourage the use of these terms for synonymous lesions but recognize that they are used synonymously for our newly described MIN.
Malignant neoplasia
The most neutral term for a neoplasm is tumor. The term simply implies a space occupying mass without known biological potential. However, it is generally applied only to masses that are considered neoplastic. Tumor should be applied to all biologically uncharacterized masses thought to be neoplastic but without proven invasion or proven metastasis. The mammary glands of mice frequently have non-invasive, low-grade neoplasms without evidence of metastases. These large focal tumors without known metastases or without proven invasion are considered adenomas. Only when invasion or metastasis is observed can the modi®er carcinoma or adenocarcinoma be justi®ed.
Criteria for malignancy The malignant potential can be judged by three criteria: (1) the histological demonstration of invasive behavior; (2) demonstration that these tumors actually metastasized; or (3) experimental assessment of biological potential by transplantation of the mass.
The biological potential can best be evaluated on the basis of biological observation and experimentation. The time-honored operational criteria in the mouse mammary biology are: (1) identi®cation of the lesion in-situ; (2) isolation of the lesions by surgical extirpation; (3) transplantation into a gland free mammary fat pad and into the subcutaneous fat of syngeneic or immunocompromised hosts (Cardi, 1984; Medina, 1996; Morris et al., 1990) . Transplants of normal mammary gland will result in outgrowth of a normal mammary tree in the fat pad but no growth in the subcutaneous tissue. The normal mammary outgrowth will survive for only a limited number of 3 ± 5 transplantions. Premalignant hyperplastic mammary lesions will ®ll the mammary fat pad with hyperplastic outgrowths that are immortal. They can be serially transplanted indefinitely but will not grow as subcutaneous transplants. Their malignant potential can be judged by the number of malignant tumors that arise secondarily from the outgrowth. In contrast, lesions that are completely transformed will grow as either subcutaneous or mammary fat pad transplants that may or may not metastasize but will continue to grow in either site.
Morphological criteria for malignancy can also be applied. Acceptable criteria include invasive growth patterns (Figure 3g ) or metastasis. Many GEM and non-GEM tumors appear to be more expansile than invasive and, frequently, have a relatively low-grade cytology (Figure 3h ). The histological demonstration of malignant potential requires adequate sampling of the tissue surrounding the tumor and harvesting of potential metastatic sites, particularly the lungs. However, caution must be exercised in correlating tumor phenotype with metastases. Many, if not most, transgenic mice have multifocal mammary tumors. Without experimental veri®cation, it may be impossible to prove that the metastasis came from any one of the many mammary tumors.
In a like manner, caution must be used when applying molecular criteria for neoplasia. Non-GEM premalignant mouse mammary hyperplasias are clonal and frequently have loss of heterozygosity (Cardi, 1984; Marchetti et al., 1995; Morris et al., 1990) . Even lesions with a low risk of malignant progression have these molecular characteristics. Since the individual lesions can be isolated and transplanted for comprehensive study of their natural history, the GEM are excellent experimental models for the testing of molecular concepts of neoplastic progression.
Grading Histological and cytological grading has proven useful in assessing the biological potential of human breast cancer (Charpin et al., 1995; Genestie et al., 1998; Le Doussal et al., 1989) . The grading systems attempt to establish standard criteria for histological organization, mitotic rate and nuclear atypia. All MIN and neoplasms should be graded to determine which cytological criteria correlate with outcome.
The low-grade lesions are characterized by the presence of well-organized glandular patterns, hyperchromatic nuclei without signi®cant pleomorphism but with reduced cytoplasm. The mitotic rate is increased (Figures 2a,b and 3h) . High-grade lesions have less dierentiated glands, more nuclear pleomorphism and a higher mitotic rate (Figure 3c,f,g ).
In general, the GEM models have much higher grade tumors that in the non-GEM, spontaneous tumors in mice. Unfortunately, the cytological grade in GEM does not always correspond with the rate of metastasis (Cheung et al., 1997) . However the GEM models provide an excellent opportunity to determine which factors are the most prognostically signi®cant.
Property and topography
Although the categories of property and topography are self explanatory, several aspects need emphasis. The properties are not diagnostically signi®cant terms but may be used to modify the diagnosis, providing ancillary information about the tumor. They should not be used in isolation but only to modify the primary diagnosis. The topographical data is signi®cant in evaluating the biology of the lesion. The modi®er diuse' means that all of the mammary gland is involved, implying a universal or systemic phenomenon. If only portions of the gland are involved, the word multifocal is more appropriate. The use of multifocal or focal in relation to proliferating cells suggests a neoplastic event. These modi®ers should be included in descriptions of any lesion so that the data can be collected for further study.
Inducer (etiology)
GEM models are being used to evaluate the role of various genes in mammary cancer. With increasing frequency, the GEM models are being experimentally manipulated. Experimental introduction of exogenous hormones, exogenous viruses, carcinogens and other modi®ers is designed to change the natural history of the disease. The morphology will also change and the experimental inducer must be explicitly noted. Some factors are discussed below.
Non-GEM mouse tumors
Three types of lesions are typical of MMTV-induced tumors (Figure 2 ). Veterinary pathologists have traditionally described them as acinar, tubular or solid. These MMTV-induced lesions have suciently unique characteristics and their origin is known that they should be recognized and acknowledged by all pathologists. Interestingly, many carcinogen-induced tumors are either adenosquamous or undierentiated but additional tumor types occur such as adenomyoepitheliomas (Rehm, 1990) . Again, the patterns and origins are well known. However, the morphology of chemically induced tumors may depend on the strain and cell of origin (Rehm, 1990) .
Mammary tumors in GEM
MMTV-type tumors Interestingly and reassuringly, GEM models generated with oncogenes originally identi®ed by MMTV insertional mutagenesis developed tumors that closely resembled those induced by the MMTV viruses. The MMTV-LTR/int2(FGF3), wnt1/int2, notch 4 and wnt10b transgenes produced MMTV-type tumors. MMTV-LTR promoted transgenes (wnt1 and wnt10b) produced tumors more closely resembling the acinar tumors (Figures 2 and 3) .
It is important to note that many other transgenic animals also produced sporadic tumors with squamous metaplasia (adenosquamous carcinoma or adenoacanthoma) (Figure 2c ). This tumor phenotype is also frequently observed in association with chemical carcinogenesis in BALB/c and C3H strains (Medina, 1976 (Medina, , 1988 Medina and Warner, 1976) . The mammary epithelium of older mice under chronic prolactin stimulation commonly has squamous metaplasia (Huseby et al., 1985) . It is important when interpreting tumors with squamous metaplasia in GEM mice to consider the possibility that these tumors are not due to the genetic manipulation, but are sporadic tumors. It must be remembered that factors that induce squamous metaplasia in other mice can also be operative in GEM mice.
GEM signature tumors Several of the models present in the Annapolis slide set or from the Panel's private archives, had tumors with unique phenotypes. Such signature phenotypes were observed in association with myc, c-erbB2, ras, and ret1 (Figure 4 ). The best example was probably the myc-type tumors that have relatively large cells with large, pleomorphic nuclei with a course chromatin and prominent nucleoli. The cytoplasm also tended to relatively abundant and darkly amphophilic. This signature myc phenotype was seen under the in¯uence of dierent promotors, in tumors with dierent grades of dierentiation and in combination with dierent secondary transgenes (compare Figures 3c,h and 4b) . In contrast, the cerbB-2 tumors have much more uniform, smaller nuclei with a delicate chromatin and abundant pink cytoplasm (Figure 4a ). The erbB2 tumors tend to grow as solid expansile nodules of cells. Ras associated tumors have a smaller more regular nucleus and abundant reddish cytoplasm (Figure 4c ). The ras tumors tend to grow as solid papillary lesions resembling transitional cells of the urinary bladder. The ret1 tumors formed small crowded glands with large pleomorphic nuclei and scanty reddish cytoplasm (Figure 4d ). The unique characteristics of each transgenic tumor type are very signi®cant because they suggest that tumor phenotype can be correlated with the molecular alteration in mice and perhaps in human (see below) (Cardi et al., 1991) .
Some`signature' tumor phenotypes have also been observed in some human breast cancers. For example, the so-called ductal carcinoma in situ (DCIS) of the comedo type has a distinctive morphological atypia and central necrosis. This form of DCIS generally overexpresses c-erbB2 (Barnes, 1993) . More recently, morphological features which distinguish between BRCA1-and BRCA2-associated human tumors have been described (Lakhani et al., 1998) . Some special types of human breast cancer appear to be associated with particular genetic alterations (Armes et al., 1998) , suggesting that human tumor phenotype is also heavily in¯uenced by genotype. We expect that additional phenotypes will be correlated with genotype leading to a molecular classi®cation for both human and murine breast cancers. However, whether the same`signature' phenotype will be induced by a given genetic alteration in the dierent genetic backgrounds of human and mouse is not yet clear.
It should be emphasized that the unique GEMinduced phenotypes are signature tumors that are found solely or primarily associated with a particular transgene. Tumors with other, less characteristic, phenotypes do also appear in association with the same transgene at varying frequencies (Cardi et al., 1991) . A signature tumor type appears to be occasionally induced by an entirely dierent transgene. These exceptions could indicate the recruitment or overexpression of dierent ancillary genes. The mammary biologist studying any given model system must be alert to appearance of these non-signature tumors.
GEM tumors that mimic human tumors Finally, some of GEM models contained lesions that closely resembled human breast neoplasms (Cardi and Wellings, 1999) . Although the similarities were impressive, it should be emphasized that they tended to be represented in restricted foci of tumors and not necessarily the entire tumor. As a result, an experienced surgical pathologist would confuse few mouse tumors with human lesions. The closest resemblance was found amongst the more poorly dierentiated phenotypes. However, transgenes such as c-erbB2 produced a range of lesions that resembled solid or comedo forms of so-called DCIS of humans (Cardi and Wellings, 1999) . SV-40 Tag also produced DCIS type lesions (Shibata et al., 1996) . Examples of notch4-induced lesions produced a unique ductal atypia that mimics DIN or atypical hyperplasia (Tavassoli, 1997 (Tavassoli, , 1998 Tavassoli and Norris, 1990) . Papillary carcinomas that could mimic human cancer were seen in many of the transgenic models such as MMTV-LTR/cyclin D1, met1 and BGL/IGF2 (Cardi and Wellings, 1999) . Lastly, tumors with regions densely sclerotic stroma can be found associated with the myc, PyV-mT, SV-40 Tag, WAP/int-3 and src transgenes (Figure 3f,g) (Cardi & Wellings, 1999) .
Multi-genic GEM tumors A number of GEM tumors that develop in animals with two or more engineered genes have been described. These bigenic or trigenic animals produce tumors that are neither mixtures of the signature tumor phenotype nor a unique phenotype (Cardi, 1995 (Cardi, , 1991 Cardi and Munn, 1995) . Rather, tumors in multigenetic mice tend to express the phenotype of the dominant transgene. For example, the myc transgene is dominant in combination with transgenes such as ras, erbB2, BCL2, TGFa, and heregulin (Cardi et al., 1991) . All mice with the myc transgene, independent of promotor system, develop mammary tumors that have myc-type cytology (Figures  3c and 4b) . As might be expected, when a transgene is coupled with mice with targeted mutations of tumor suppressor genes, the tumors always resemble the transgenic signature pattern. In some targeted mutations such as p53, the overall pattern of the transgene is retained but with a tendency towards higher cytological grades with increasing nuclear pleomorphism and aneuploidy.
Biological/experimental context
The pathologic interpretation of GEM mammary lesions requires knowledge of the biological and experimental context in which the lesions developed. In a hormone sensitive organ such as the mammary gland factors such as parity, pregnancy, lactation, involution and endogenous or exogenous hormones are extremely important (Russo et al., 1990) . The information should accompany all samples submitted to the pathologist. Preferably, the pathologist should be consulted in advance and be involved and informed about the experimental design and sampling times.
The promotor system used to create the GEM is particularly important and should be recorded as an important part of the diagnostic information. The promotor in many GEM models in¯uences the phenotype. For example, the pattern observed with TGFa is quite dierent in the WAP based systems as compared to the MMTV-LTR based systems ( Figure  3i,d,g,h) . On the other hand, myc is such a dominant transgene that its phenotype appears to be independent of the promotor (Figure 3c,g ). The promotor, in some cases, appears to eect the cell of origin. For example, C(3)1 appears to be associated with lesions in the major collecting ducts while MMTV-LTR appears to be more likely associated with lesions with a TDLU origin (Shibata et al., 1996) . These conclusions are based on a very limited set of samples but emphasize the need to record the promotors.
Ancillary tests and immunophenotyping
The Panel repeatedly sought the types of additional information provided by ancillary tests such as in situ hybridization, image analysis and immunophenotyping. This type of information has proven to be extremely valuable in the understanding and interpretation of human breast diseases. Some of this information is now incorporated into the routine assessment of human breast cancers. However, the literature has very few examples of systematic or comparative immunophenotyping of tumors in GEM model systems. As a result, the Panel could not be provided with information that it considered important in its interpretation of the biology and natural history of the disease.
Immunocytochemical techniques have proven useful in documenting critical biological events in human breast cancer. The Panel, therefore, recommends that all mammary models be characterized by immunohistochemistry and/or in situ hybridization studies. Table  5 provides the categories that should be studied and some of the recommended markers where available.
Pathobiology
Our understanding of the pathology of human breast cancer is based on the correlation of each morphological entity with molecular and clinical-pathological parameters. Because large numbers of cases of individual types of human breast cancer have been studied within the context of clinical trials, it has been possible to produce predictive information on likely survival and metastatic potential for an individual case. The major diculty that faced the Panel was insucient information to predict the natural history of the disease. The vast majority of animals with MIN lesions had no accompanying data to predict the likely behavior and potential progression of the lesions. In order to identify the most appropriate models for extensive molecular analysis, further and more detailed studies of their natural history must be done. An experienced pathologist who is part of the research team must study the pathology of these animals over a prolonged time course. The investigator is obliged to collect the appropriate information so that patterns of morphological progression and biological potential can be established.
Experimental, clinical and pathological information is required for interpretation of the mammary pathobiology. The Panel has created report forms for the biologist and the pathologist that feature the key data points and descriptors (see Appendix). These forms are designed to guide both teams in the recording of data. The collection of this data is essential. The principal investigators should concentrate on collecting observations that lead to an understanding of the natural history of the disease.
Mouse models aord an excellent opportunity to study and understand the evolution of breast disease. More attention needs to be given to the time course of the growth and development of the mammary gland in these model systems. Many model systems develop early abnormalities that, in and of themselves, provide insight into mammary biology. When coupled with neoplastic development, these insights will lead to advances in the understanding and treatment of human breast cancer. For example, mammary whole mount and histological specimens should be taken from GEM during development at 4, 8, 12 and 14 weeks after birth and pregnancy, lactation and involution. Age and parity matched control mice from the investigator's own colony are essential for adequate interpretation.
The starting and terminal points of tumor progression deserve particular attention. On a purely cytological basis, the Panel approves of the term MIN to denote intraluminal proliferations of epithelium that have signi®cant nuclear atypia. However, this concept must be validated by a combination of tissue transplantation to prove the biological potential of such atypical lesions and by molecular analysis to demonstrate properties such as LOH and clonality associated with other such lesions. The role of these techniques in assessing the biology has been described previously.
Many of the mammary tumors in the slide set were relatively low grade and typically had expansile or pushing margins rather than outright invasion. By most criteria, such lesions are intraepithelial neoplasms, nonmalignant neoplasms or adenomas. However, the veterinary community is very familiar with such tumors resulting in pulmonary metastases and properly regards them as malignant tumors. Since such information is not always available in the GEM model systems, it needs to be systematically collected. The necropsy prosector needs to be carefully observant of the lung and other potential sites of metastasis. The pathologist needs to search more carefully for evidence of vascular invasion and microinvasion of the stroma.
Finally, the research community needs to remember that many tumor cells form emboli that may appear in the lung but do not colonize the lung. This distinction is critical. The investigator should not count small intravascular collections of cells as`pulmonary metastasis'. Many of the small tumor emboli are only transient in the lung and will not colonize the lung. We recommend that only those foci that expand the lumen of the blood vessel or invade the wall of the blood vessel be considered as pulmonary metastasis.
Pathologic technique
The quality of many of the samples found in the Annapolis slide set suggested to the Panel that some investigators need guidance in the specimen sampling, ®xation and processing. An outline of recommended procedures for the necropsy of animals and for specimen ®xation and processing is appended. These recommendations are re¯ected in the forms that are also appended.
Several aspects of specimen procurement and processing need emphasis. First is the need for harvesting of the`normal' host tissue adjacent to the lesion. While the molecular analysis of tumors requires samples without normal tissue, the pathologic analysis requires the interface between the host and its tumor. The interface between the two contains valuable information about the growth characteristics of the tumor (invasive versus expansile) and the reaction of the host to its tumor. Further, the adjacent mammary tissue often contains atypical regions that give important insight into neoplastic progression and the mammary pathobiology associated with the speci®c gene. On excision of the tumor, cut widely around the mass and leave all surrounding tissues attached including the overlying skin, adipose subcutaneous tissues and underlying musculature. On trimming the mass, be sure to include attached representative sections of normal adjacent tissues.
Inadequate ®xation appears to be a common problem. The quality of ®xation on some specimen slides suggest either that the sample was not exposed to the ®xative long enough to permeate the entire mass, the ®xative had exceeded its shelf life or the ratio of ®xative to tissue was inadequate. In some cases, the pathologist cannot accurately assess the preparations. In others, poor ®xation precludes immunohistochemistry or in situ hybridization. The investigator should also note that the precise procedures for sampling and processing would depend on the research design. Some antigens are destroyed or masked by speci®c ®xatives. Standard formalin ®xation does not provide as good nuclear detail as metal or acidic based ®xatives. Alcohol is preferred for nucleic acid extraction or in situ hybridization but creates shrinkage artifacts. Once the specimen is ®xed, it can be`post-®xed' to recover some antigens or cytological detail. For example, antigens and nuclear detail in formalin-®xed tissue can be recovered by post-®xation in mercury based ®xatives such as B5. Investigators are encouraged to incorporate an experienced pathologist into their research team so that such details can be worked out in advance of harvesting of the samples.
Finally, while most investigators are using the whole mount technique, apparently some groups do not routinely use whole mounts to evaluate their animals. This simple technique allows survey of the entire mammary structure and should be systematically used on all studies of rodent mammary biology.
The pathologist
As indicated above, investigators who wish to have an accurate assessment of their model need to incorporate an experienced pathologist into their team throughout the course of the research program. Pathology is the study of disease. Pathology is not simply the naming of histological patterns. As discussed throughout this essay, accurate interpretation of the disease process requires a thorough knowledge of the structure and function of the mammary gland, the context in which the disease occurs, its natural history, and etiology. A tumor is not a cancer just because someone declares it so. It is only diagnosed as a cancer when morphologic evaluation is coupled to careful studies of the natural history of the disease. The pathologist is the person trained to assist the investigator in integrating this information.
The introduction of genetic engineering into mouse pathology has provided a unique and exciting new biology. The Annapolis Pathology Panel was composed of a cross section of expertise in experimental, surgical and veterinary pathology. This panel of experts often found the mouse models presented were far beyond their experience and, therefore, dicult to interpret. Our recommendations are based on our combined experience and expertise. We suspect that no single pathologist has such a combination of experts readily available and is at risk of misinterpreting slides from genetically engineered animals. The Panel, therefore, recommends that a panel be developed to review slides from various NCI grantees. The panel will help educate the local institutional pathologist by sharing their expertise and bring a more standard nomenclature to transgenic pathology. The panel can be modeled after those that have been so successfully used by the organized cooperative oncology groups in the United States and Europe. The scienti®c community will bene®t through the training of local pathologists and the rapid recognition of the unique histopathological aspects of their animals. The inclusion of surgical, experimental and veterinary pathologists on such a national panel will enhance the study of comparative pathology of model systems.
Comparative pathology of the model systems
The Annapolis slide set documented that GEM produce categories of mammary tumors that are not seen in MMTV-induced or other experimentally induced mouse mammary tumors. Some of the tumors have patterns that mimic the histopathology of human breast lesions in great detail. These intriguing lesions merit much more intense study as they promise to unlock the molecular mysteries currently facing us in human breast cancer. In fact, all of the genes represented in the slide set and other models merit further study because they all inform us of the normal and abnormal biology of the mammary gland.
The National Cancer Institute has challenged the scienti®c community to develop a molecular classification of human tumors. The mouse mammary biologists have already started the marriage between pathology and molecular biology of cancer by creating animals with known genetic abnormalities that have distinctive morphological lesions. As we learn the rules of abnormal structure and function from the mouse, we should apply them to human breast cancer.
One needs to be mindful that the mouse is a dierent species. No matter how exciting the similarities, there are dierences between murine and human mammary cancer. Some of the more obvious or common similarities and dierences are listed in Table  6 .
The Panel was encouraged to learn that the molecular biologists already have plans to address Table 6 Comparison of human and mouse mammary biology
Similarities Dierences
Molecular lesions causing breast cancer in humans have proven to cause breast cancer in GEM Similar morphological patterns of lesions appear in both species Development of cancer consistent with multi-hit kinetics Breast cancers in both species are metastatic Both species have distinctive host responses to the cancers Breast cancer is frequently hormone independent Some molecular lesions causing breast cancer in mice have not been found in human breast cancer The morphology of most mouse tumors does not resemble the common human breast cancers Some transgenes appear to be associated with one-hit kinetics Most mouse tumors metastasize to the lung. Most human tumors metastasize to the regional lymph nodes The mouse generally does not respond to its tumor with as much ®brosis and in¯ammation Half of the human breast cancers are hormone independent. Most mouse tumors are hormone independent many of these dierences by creating new types of promotors, constructs and transgenes. While no one murine model system may represent the complete model system, increasing the biological and morphological similarities to human cancer will be aorded by careful attention to speci®c scienti®c questions raised in the study of clinical breast cancer. The Annapolis Meeting has reinforced the need of the scienti®c community to optimize their communication. Towards this end, the Panel and organizers have posted over 800 annotated images concerning the comparative pathology of GEM and human breast cancer at URL: http://histology.nih.gov/. In addition, a comprehensive table showing the entire slide set is available at the same URL. We are in the process of developing an interactive CD-ROM to introduce scientists and students to the pathobiology of the mouse mammary gland. This program will be available through and have appropriate educational hot links to the resources on the mammary site at NIH. We hope that this resource will serve to quickly close the gap between morphologic and molecular biology.
Summary of recommendations
1. An interim descriptive morphology-based nomenclature be applied to mammary lesions in mice until sucient knowledge of their natural history allows a biology based classi®cation system.
2. The development of a`clinical' classi®cation be deferred until the biology of the atypical intraluminal lesions is more adequately understood. 3. Detailed comparative studies using ancillary techniques such as immunohistochemistry and in situ hybridization be undertaken to establish relationships between human and murine cancer. 4. Standard protocols for the sampling, collection, processing, and reporting of specimens be adopted by the scienti®c community to ensure more uniform and thorough analysis. 5. Funding agencies should strongly encourage that research teams studying animal models of disease include an experienced pathologist with an interest in mammary biology and pathology to ensure careful morphologic evaluation. 6. NIH should establish a panel of experts for review of murine mammary pathobiology so that the necessary degree of experience can be developed and disseminated.
Ulrike Wagner for their excellent technical assistance
IDEALIZED MOUSE WORKUP FOR MAMMARY TUMORIGENESIS STUDIES
The following outline is provided as a guide for maximizing the information obtained from your mouse. Since considerable information can be obtained from analysis of microscopic changes in the mammary gland, it is particularly important to give the pathologist representative``uninvolved'' mammary tissue in addition to gross mammary lesions. This can give insight into the preneoplastic processes occurring in your model.
PROCEDURE:
